Wednesday, July 8, 2026

Drug profile · INN

estrogens, conjugated

estrogens, conjugated (PMB 200) is a estrogen receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — estrogens, conjugated
US status
approved
Class
Route
ORAL-28
Patents
0
Programs
3
Data quality
0.84

Quick answer

estrogens, conjugated (PMB 200) is a estrogen receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.

Key facts

INN estrogens, conjugated
Brand PMB 200
Mechanism Estrogen receptor agonist
Target Estrogen receptor
Route ORAL-28
Formulation INJECTABLE

Mechanism of action

Estrogen receptor agonist

Primary target: Estrogen receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Synthetic Conjugated estrogens, B Phase 3 · Teva Pharma · Menopause
  2. conjugated estrogens Phase 3 · Ultragenyx UK · Osteoporosis
  3. EG-70 (phase 1) Phase 2 · Shanghai Antengene Corporation · Superficial Bladder Cancer

Related & competitor drugs

  1. estradiol Estrogen receptor alpha agonist
  2. estradiol valerate Estrogen receptor alpha agonist
  3. estrogens, conjugated synthetic a Estrogen receptor agonist
  4. estropipate Estrogen receptor alpha agonist
  5. ethinyl estradiol Estrogen receptor alpha agonist
  6. fulvestrant Antineoplastic and immunomodulating agents (L02)

Frequently asked questions

What is estrogens, conjugated?

estrogens, conjugated (PMB 200) is a estrogen receptor agonist. Route of administration: oral-28. Current US regulatory status: approved.

What is the brand name for estrogens, conjugated?

PMB 200 is a marketed brand name for estrogens, conjugated. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of estrogens, conjugated?

estrogens, conjugated has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.